MiNK Therapeutics Q2 loss narrows on expense discipline

MiNK expects additional data from the randomized Phase 2 trial in early 2027.

The company is expanding patient enrollment for its trial in Ukraine and activating U.S. clinical centers. It is also establishing international access infrastructure through a paid named-patient program in Brazil.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell". The average consensus recommendation for the biotechnology & medical research peer group is "buy".

Wall Street's median 12-month price target for MiNK Therapeutics Inc is $39.00, about 243.3% above its August 12 closing price of $11.36.

MiNK Therapeutics said its second-quarter net loss narrowed year over year, reflecting continued expense discipline.

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Loss Per Share		$0.62
Q2 Net Loss		$3.10 mln

The company advanced its lead cell therapy, agenT-797, into a randomized Phase 2 trial for acute lung injury and ARDS, with initial patients showing clinical improvement and no major serious adverse events.

MiNK also launched a paid international named-patient access program for agenT-797, generating program revenue and building cross-border infrastructure.

Early clinical and biological data indicated reduced inflammatory markers and signs of immune recovery and tissue repair following agenT-797 administration.